Paclitaxel poliglumex
- Generic Name
- Paclitaxel poliglumex
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 263351-82-2
- Unique Ingredient Identifier
- TQ64FZ98ZN
- Associated Conditions
- -
- Associated Therapies
- -
Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- CTI BioPharma
- Registration Number
- NCT00054210
- Locations
- ๐บ๐ธ
Clinical Trials and Research Associates, Incorporated, Montebello, California, United States
๐บ๐ธOmni Healthcare, PA, Melbourne, Florida, United States
๐บ๐ธColumbia Comprehensive Cancer Care Clinic, Columbia, Missouri, United States
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- CTI BioPharma
- Registration Number
- NCT00054197
- Locations
- ๐บ๐ธ
Cooper Green Hospital, Birmingham, Alabama, United States
๐บ๐ธWestern Washington Oncology, Incorporated, Olympia, Washington, United States
๐บ๐ธNew York Oncology Hematology, P.C. - Latham, Latham, New York, United States
Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 350
- Registration Number
- NCT00054184
- Locations
- ๐บ๐ธ
Saint Joseph Oncology, Incorporated, Saint Joseph, Missouri, United States
๐บ๐ธGabrail Cancer Center - Canton Office, Canton, Ohio, United States
๐บ๐ธMontana Cancer Specialists, Missoula, Montana, United States
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 78
- Registration Number
- NCT00045682
- Locations
- ๐บ๐ธ
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.